Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.36 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.34 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10215355 | 0.84 | LDHA (0.45) | EPRS1IGFBP3KMOP2RY14SLC6A2 | |
| SCHEMBL10215309 | 0.79 | RAB9A (0.43) | — | |
| SCHEMBL10215332 | 0.79 | ALDH1A1 (0.43) | ERN1 | |
| SCHEMBL10215325 | 0.78 | SCD (0.40) | ERN1 | |
| SCHEMBL10215333 | 0.77 | SCD5 (0.37) | ERN1 | |
| SCHEMBL10215305 | 0.77 | EPRS1 (0.36) | ERN1EPRS1IGFBP3KMONPBWR1 | |
| SCHEMBL10215334 | 0.75 | SCD5 (0.47) | — | |
| SCHEMBL10215322 | 0.75 | EPRS1 (0.53) | EPRS1IGFBP3KMOP2RY14SLC6A2 | |
| SCHEMBL3699862 | 0.73 | ERN1 (0.45) | ERN1KMOCNR2NPBWR1 | |
| SCHEMBL10215608 | 0.71 | RBP4 (0.36) | EPRS1IGFBP3P2RY14ASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | ERN1 163/4885EPRS1 2425/4885IGFBP3 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.